HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

BACKGROUND: The human leucocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Understanding the benign HLA ligand repertoire is a prerequisite to define safe T-cell-based immunotherapies agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcu, Ana, Bichmann, Leon, Kuchenbecker, Leon, Kowalewski, Daniel Johannes, Freudenmann, Lena Katharina, Backert, Linus, Mühlenbruch, Lena, Szolek, András, Lübke, Maren, Wagner, Philipp, Engler, Tobias, Matovina, Sabine, Wang, Jian, Hauri-Hohl, Mathias, Martin, Roland, Kapolou, Konstantina, Walz, Juliane Sarah, Velz, Julia, Moch, Holger, Regli, Luca, Silginer, Manuela, Weller, Michael, Löffler, Markus W., Erhard, Florian, Schlosser, Andreas, Kohlbacher, Oliver, Stevanović, Stefan, Rammensee, Hans-Georg, Neidert, Marian Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054196/
https://www.ncbi.nlm.nih.gov/pubmed/33858848
http://dx.doi.org/10.1136/jitc-2020-002071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054196/
https://www.ncbi.nlm.nih.gov/pubmed/33858848
http://dx.doi.org/10.1136/jitc-2020-002071

Ejemplares similares